PARP Inhibitor Market to Witness Astonishing Growth at a CAGR of 27.4% during Forecast Period | Leading Players: Bristol - Myers Squibb, AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Merck KGaA

Global PARP Inhibitor Market reached USD 924 million in 2018, to expand at a CAGR of 27.4% over the forecast period.

A promising product pipeline of PARP inhibitors has shown positive results in recent times. The improved safety profile of these drugs compared to cell-therapy drugs along with increased U.S. FDA approval for these drugs is expected to spur the growth of the PARP Inhibitor Market. Another factor contributing to the development of the market are the rising incidences of cancer across the globe.

Click here to get sample of the premium report: https://www.quincemarketinsights.com/request-sample-60838#utm_source=hp&utm_medium=openpr&utm_campaign=hp

A majority of elderly people suffer from cancer. According to the Administration for Community Living, geriatric population (people aged 65 years or above) in the U.S. stood at 46.2 million in 2014. Thus, increase in elderly population is likely to drive the global PARP inhibitors market during the forecast period.

However, the small patient pool for the treatment, side effects associated with the drugs, drug resistance among patients and demanding regulatory requirement for the approvals of the PARP inhibitors may hamper the growth of the PARP inhibitors market. In addition, the late-stage recall of a few developmental drugs is also expected to impede the growth of PARP inhibitors.
The report provides information on the current scenario, detailed outlook on the global PARP Inhibitor market with thorough analysis of different segments which comprises of By Drug (Lynparza, Niraparib, Rucapairb, Talazoparib, Veliparb), Indication (Overian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer), Distribution Channel (Hospitals, Retail Pharmacies, Online Channels).

Get ToC for the overview of the premium report: https://www.quincemarketinsights.com/request-toc-60838#utm_source=hp&utm_medium=openpr&utm_campaign=hp

Major Companies profiled in the report which are key players in the global PARP Inhibitor market are Bristol - Myers Squibb, AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Merck KGaA, Repare Therapeutics Inc., Genentech, Inc., Sierra Oncology, Inc., Ono Pharmaceutical Co., LTD., Karyopharm Therapeutics Inc., and Jiangsu Hengrui Medicine Co., Ltd.

Recent trends of collaborations of local and global companies and the growing support of government and healthcare agencies are expected to have a synergistic effect on market growth. Such collaboration and exchange of technologies help in speeding up the development and boost the market competition.

• In July 2017, AstraZeneca and Merck & Co., Inc. declared collaboration for the commercialization and development of AstraZeneca's LYNPARZA (olaparib) made for the treatment of multiple cancer types.
• According 2018 statistics of the World Health Organization, cancer is responsible for an estimated 9.6 million deaths in 2018, which is the second leading cause of death globally. In 2018, about 1 in 6 deaths occurred due to cancer.

Regional Analysis

North America holds a dominant position in the global PARP inhibitor market. The region's dominance is attributable to due to rising R&D activities by key players, better reimbursement policies, and availability of advanced healthcare infrastructure helps to maintain a larger market share in the global PARP inhibitors market by the regions over the forecast period.

• For instance, in May 2019, AstraZeneca and Merck received the Health Canada approval for Lynparza as a monotherapy maintenance treatment for adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer.

Asia Pacific PARP inhibitors market is anticipated to present lower growth opportunities owing to a lack of regulatory protection for innovative drugs and reimbursement policies in the region.

Speak to analyst before buying this report: https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-60838#utm_source=hp&utm_medium=openpr&utm_campaign=hp

An Overview of the report
1. The report offers insights on the global overview of the PARP Inhibitor market
2. The recent market developments are scrutinized to project latest trends along with growth rate projections
3. Deeper understanding of the competitive landscape of the major companies operating in the market
4. New Opportunities and challenges for the global PARP Inhibitor market
5. Study of innovation and technological advancements in the industry

Analysts have undertaken research based on in-depth understanding of the market with qualitative and quantitative data. The market has been segmented into various segments such as product and room type along with regional analysis. The segments and sub-segments offer insights on current and potential growth trajectories.

Market Segmentation:

By Drug
• Lynparza
• Niraparib
• Rucapairb
• Talazoparib
• Veliparb

By Indication
• Overian Cancer
• Breast Cancer
• Prostate Cancer
• Pancreatic Cancer

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

North America
o By Country (US, Canada, Mexico)
o By Drug
o By Indication
o By Distribution Channel

Western Europe
o By Country (Germany, UK, France, Italy, Spain, Rest of Western Europe)
o By Drug
o By Indication
o By Distribution Channel

Eastern Europe
o By Country (Russia, Turkey, Rest of Eastern Europe)
o By Drug
o By Indication
o By Distribution Channel

Asia Pacific
o By Country (China, Japan, India, South Korea, Australia, Rest of Asia Pacific)
o By Drug
o By Indication
o By Distribution Channel

Middle East
o By Country (UAE, Saudi Arabia, Qatar, Iran, Rest of Middle East)
o By Drug
o By Indication
o By Distribution Channel

Rest of the World
o By Region (South America, Africa)
o By Drug
o By Indication
o By Distribution Channel

Reasons to Buy This Report:
• Market size estimation of the PARP inhibitor market on a regional and global basis
• Unique research Usage for market size estimation and forecast
• Profiling of major companies operating in the market with key developments
• Broad scope to cover all the possible segments helping every stakeholder in the market

Customization:
We provide customization of the study to meet specific requirements:
• By Segment
• By Sub-segment
• By Region/Country

Contact:
Quince Market Insights
Office No- A109
Pune, Maharashtra 411028
Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 121 364 6144
Email: sales@quincemarketinsights.com
Web: www.quincemarketinsights.com

ABOUT:
QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the world's most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

This release was published on openPR.